首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
【24h】

A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.

机译:淀粉样蛋白-β(1-42)作为辅助因子通过吸血蝙蝠纤溶酶原激活物和重组人组织型纤溶酶原激活物激活纤溶酶原的比较研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The activity of both human tissue-type plasminogen activator (t-PA) and the PA from the saliva of the vampire bat, Desmodus rotundus, (DSPA) is critically dependent on the presence of a cofactor. The most efficient cofactor for both PAs is fibrin, but fibrinogen and amyloid beta peptides also have cofactor activities for human t-PA. Compared to t-PA, DSPA has a more stringent requirement for fibrin as a cofactor. The present study was undertaken to compare cofactor activities of amyloid beta 1-42 (Abeta1-42) for plasminogen activation by DSPA-alpha1 or by t-PA. The two PAs were incubated with different concentrations of glu-plasminogen, a chromogenic substrate for plasmin and 100 micro g mL (-1) of Abeta1-42, fibrinogen or fibrin as cofactor. Using the kinetic parameters directly determined from the chromogenic substrate conversion curves, we derived the relative efficacies of DSPA or t-PA in the presence of cofactor at the physiological plasminogen concentration of 2 micro M. In the presence of fibrin, the activity of DSPA was comparable to that of t-PA and 23,270-fold higher than its activity without cofactor, whereas fibrin induced only a 248-fold increase in t-PA activity. The activity of DSPA with Abeta1-42 or fibrinogen as cofactor was 485-fold lower than its activity in the presence of fibrin, while for t-PA this difference was only 26-fold. The much lower activity of DSPA as compared to t-PA with Abeta1-42 or fibrinogen might lead to fewer side effects when used for the thrombolytic therapy of stroke.
机译:人类组织型纤溶酶原激活剂(t-PA)和吸血蝙蝠(Desmodus rotundus)(DSPA)唾液中的PA的活性都主要取决于辅因子的存在。两种PA的最有效辅因子是纤维蛋白,但纤维蛋白原和淀粉样β肽对人t-PA也具有辅因子活性。与t-PA相比,DSPA对血纤蛋白作为辅因子的要求更为严格。进行本研究以比较淀粉样蛋白β1-42(Abeta1-42)的辅因子活性对DSPA-alpha1或t-PA激活纤溶酶原的作用。将两个PA与不同浓度的glu-纤溶酶原,纤溶酶的生色底物和100微克(-1)的Abeta1-42,纤维蛋白原或血纤蛋白作为辅因子孵育。使用直接从生色底物转化曲线确定的动力学参数,我们得出了在辅酶存在的情况下,在纤溶酶原生理浓度为2 micro M时,DSPA或t-PA的相对效率。在纤维蛋白存在下,DSPA的活性为与t-PA相当,比无辅因子的活性高23,270倍,而血纤蛋白仅使t-PA活性增加248倍。与Abeta1-42或纤维蛋白原作为辅因子的DSPA活性相比,在纤维蛋白存在下的活性低485倍,而对于t-PA而言,这一差异仅为26倍。与具有Abeta1-42或纤维蛋白原的t-PA相比,DSPA的活性低得多,当用于中风的溶栓治疗时,可能导致较少的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号